Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
2
17%
Ph phase_2
10
83%

Phase Distribution

0

Early Stage

10

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
10(83.3%)
Phase 3Large-scale testing
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Terminated(1)

Detailed Status

Completed11
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
91.7%
Most Advanced
Phase 3

Trials by Phase

Phase 210 (83.3%)
Phase 32 (16.7%)

Trials by Status

completed1192%
terminated18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

An Open Label Study to Evaluate G17DT Compared to Gemcitabine

NCT03200821
completedphase_2

Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.

NCT02223078
completedphase_2

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

NCT02521649
completedphase_2

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

NCT02518529
completedphase_2

Effect of G17DT in Patients With Stage II/III Colorectal Cancer

NCT02518373
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03200821Phase 3

An Open Label Study to Evaluate G17DT Compared to Gemcitabine

Completed
NCT02223078Phase 2

Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.

Completed
NCT02521649Phase 2

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Completed
NCT02518529Phase 2

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

Completed
NCT02518373Phase 2

Effect of G17DT in Patients With Stage II/III Colorectal Cancer

Completed
NCT02450032Phase 2

Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer

Completed
NCT02233712Phase 2

Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.

Completed
NCT02228785Phase 2

A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer

Terminated
NCT02181465Phase 2

Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.

Completed
NCT02118077Phase 3

Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer

Completed
NCT02098291Phase 2

An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma

Completed
NCT02098239Phase 2

Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12